A novel therapeutic giving cancer patients new hope.

We are focused on rapidly advancing our lead therapeutic candidate, GP-2250, for the treatment of multiple cancer types including pancreatic and ovarian cancers.

Learn More

Our Science

Disrupting cancer cell metabolism.

Our unique and novel mechanism of action selectively disrupts the energy metabolism of cancer cells leading to cancer cell death as well as impacting nuclear factor-κB (“NFκB”) which effects cancer cells’ ability for protein synthesis and DNA transcription thereby restricting cancer cell growth and proliferation.

Video Image

Discover Our Science


Focused on Addressing Unmet Needs for Patients with Cancer.

Icon Pancreatic Cancer


Icon Ovarian Cancer


Icon Additional Targets


Melanoma, Squamous Cell, Breast, Colorectal

Preclinical research with GP-2250 demonstrated significant anti-cancer activity in numerous established and primary cell lines. GP-2250’s novel MOA and degree of preclinical activity is exciting and could be a potentially important addition to the oncologists’ armamentarium to benefit patients.

Prof. Dr. med. Chris Braumann

EvK Gelsenkirchen, University of Duisburg-Essen, Germany

It is so refreshing to work with an organization that not only shares wholeheartedly in our mission to improve survival and quality of life for patients, but has truly unique science that provides new hope in the fight against cancer.

Dr. Anup Kasi, University of Kansas Medical Center

GP-2250 Phase 1 Principal Investigator

Truly novel.
Truly important.

We are on a mission to improve therapeutic outcomes for cancer patients with GP-2250, a tumor-cell selective agent with a truly novel mechanism of action.

Homepage Graphic 1x

Focused on what matters most.

While GP-2250 has demonstrated broad utility across a number of indications and therapeutic uses in preclinical and Phase 1 clinical studies, including where inflammatory cytokine suppression could be of therapeutic value, we have chosen to focus on the treatment of pancreatic and ovarian cancers as our initial targets, two conditions with a clear unmet need. Early clinical experience is promising.   

Participate in our ongoing pancreatic cancer study

Early Clinical Results Improve Quality Of Life

The Latest


Antineoplastic activity of GP-2250 in-vitro and in mouse xenograft models

R. Duane Sofia, Kathryn M. Martin and James C. Costin

Press Release – November 21, 2023

International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma

International Journal of Molecular Sciences Publishes Preclinical Data of Panavance’s Misetionamide (GP-2250) in Melanoma Misetionamide is effective in targeting and killing BRAF-mutated melanoma cells while preserving normal cells BRAF-mutated…

In Vitro Experiments on the Effects of GP-2250 on BRAF-Mutated Melanoma Cell Lines and Benign Melanocytes

Thilo Gambichler , Friederike Harnischfeger , Marina Skrygan , Britta Majchrzak-Stiller , Marie Buchholz , Thomas Müller and Chris Braumann

Press Release – October 5, 2023

Panavance to Present at the BIO Investor Forum

Panavance to Present at the BIO Investor Forum BERWYN, PA, Oct. 05, 2023 (GLOBE NEWSWIRE) — Panavance Therapeutics Inc. (“Panavance” or the “Company”), a clinical-stage pharmaceutical company advancing the development of misetionamide…